19th Feb 2016 07:10
LONDON (Alliance News) - Drugmaker AstraZeneca PLC on Friday said the European Commission has granted its Zurampic product authorisation for gout treatment in the European Union and said it has secured marketing approval for its Brilique product.
The EC has approved Zurampic in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia in adult in adults with gout.
"There has been limited therapy innovation in gout over the last 50 years. With the approval of Zurampic, we are pleased to offer a new treatment option for the many patients who are suffering from the effects of gout and who are not reaching the recommended serum uric acid treatment targets with the current standard of care," said Sean Bohen, vice-president of global medicines development and chief medical officer at the FTSE 100-listed group.
In addition, AstraZeneca said it has secured marketing approval in the European Union for its Brilique drug for the treatment of patients with a history of heart attacks.
The company said the authorisation covers the treatment of people who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca